-
-
-
-
-
-
-
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
-
-
-
-
-
-
-
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
-
-
-
-
-
-
-
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates
-
-
-
-
-
-
-
Fusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer
-
-
-
-
-
-
-
Fusion Pharmaceuticals (FUSN) to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

